Observational studyBMC cancer2024

The difference between dacomitinib and afatinib in effectiveness and safety in first-line treatment of patients with advanced EGFR-mutant non-small cell lung cancer: a real-world observational study.

Wen-Chien Cheng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.